Treatment of chronic graft-versus-host disease with bortezomib

Blood

Volumn 124, Issue 10, 2014, Pages 1677-1688

  Pai, Chien Chun Steven ^a   Chen, Mingyi ^a   Mirsoian, Annie ^a   Grossenbacher, Steven K ^a   Tellez, Joseph ^a   Ames, Erik ^a   Sun, Kai ^b   Jagdeo, Jared ^a   Blazar, Bruce R ^c   Murphy, William J ^a   Abedi, Mehrdad ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR; BORTEZOMIB; MINOR HISTOCOMPATIBILITY ANTIGEN; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; BRONCHIOLITIS OBLITERANS; CANCER INFILTRATION; CANCER RECURRENCE; CELL DIFFERENTIATION; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; DERMOEPIDERMAL JUNCTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GERMINAL CENTER; HUMAN; HUMORAL IMMUNE DEFICIENCY; MASTOCYTOMA CELL LINE; MOUSE; MOUTH INFECTION; NEUROPATHY; NONHUMAN; RESPIRATORY TRACT INFECTION; SCLERODERMA; SKIN DEFECT; SKIN PROTECTION; THROMBOCYTOPENIA; TUMOR CELL LINE; TUMOR VOLUME; WEIGHT REDUCTION; XEROSTOMIA; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CHRONIC DISEASE; CLINICAL TRIAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PATHOLOGY; SKIN; SYSTEMIC SCLEROSIS; TREATMENT OUTCOME; TUMOR CELL CULTURE;

ANIMALS; BORONIC ACIDS; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PYRAZINES; SCLERODERMA, SYSTEMIC; SKIN; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 84907013113     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-02-554279     Document Type: Article

References (33)

1. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443-458.
2. Pasquini MC, Wang Z, Horowitz MM, Gale RP. 2010 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. Clin Transpl. 2010;2010:87-105.
3. Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2011;17(1):1-17.
4. Horwitz ME, Sullivan KM. Chronic graft-versus-host disease. Blood Rev. 2006;20(1):15-27.
5. Allen JL, Fore MS, Wooten J, et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood. 2012;120(12):2529-2536.
6. Srinivasan M, Flynn R, Price A, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012;119(6):1570-1580.
7. Zhang C, Todorov I, Zhang Z, et al. Donor CD4+ T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood. 2006;107(7):2993-3001.
8. Kuzmina Z, Krenn K, Petkov V, et al. CD19(+) CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome. Blood. 2013;121(10):1886-1895.
9. Young JS, Wu T, Chen Y, et al. Donor B cells in transplants augment clonal expansion and survival of pathogenic CD4 1 T cells that mediate autoimmune-like chronic graft-versus-host disease. J Immunol. 2012;189(1):222-233.
10. Lee SJ, Flowers ME. Recognizing and managing chronic graft-versus-host disease. Hematology Am Soc Hematol Educ Program. 2008;134-141.
11. Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012;120(5):947-959.
12. Sun K, Wilkins DE, Anver MR, et al. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood. 2005;106(9):3293-3299.
13. Sun K, Li M, Sayers TJ, Welniak LA, Murphy WJ. Differential effects of donor T-cell cytokines on outcome with continuous bortezomib administration after allogeneic bone marrow transplantation. Blood. 2008;112(4):1522-1529.
14. Mulder A, Heidt S, Vergunst M, Roelen DL, Claas FH. Proteasome inhibition profoundly affects activated human B cells. Transplantation. 2013;95(11):1331-1337.
15. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med. 2008;14(7):748-755.
16. Moran E, Carbone F, Augusti V, Patrone F, Ballestrero A, Nencioni A. Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. Semin Hematol. 2012;49(3):270-276.
17. Anderson BE, McNiff JM, Matte C, Athanasiadis I, Shlomchik WD, Shlomchik MJ. Recipient CD4+ T cells that survive irradiation regulate chronic graft-versus-host disease. Blood. 2004;104(5):1565-1573.
18. Ginhoux F, Collin MP, Bogunovic M, et al. Blood-derived dermal langerin1 dendritic cells survey the skin in the steady state. J Exp Med. 2007;204(13):3133-3146.
19. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956.
20. Gomez AM, Vrolix K, Martínez-Martínez P, et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol. 2011;186(4):2503-2513.
21. Heidt S, Roelen DL, Vergunst M, Doxiadis II, Claas FH, Mulder A. Bortezomib affects the function of human B cells: possible implications for desensitization protocols. Clin Transpl. 2009;2009:387-392.
22. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99(12):4357-4363.
23. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89(12):4531-4536.
24. Matsuoka K, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra143.
25. Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood. 2009;114(4):891-900.
26. Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA. 2004;101(21):8120-8125.
27. Koreth J, Stevenson KE, Kim HT, et al. Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012;30(26):3202-3208.
28. Flynn R, Du J, Veenstra RG, et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014;123(25):3988-3998.
29. Sen R. Control of B lymphocyte apoptosis by the transcription factor NF-kappaB. Immunity. 2006;25(6):871-883.
30. Jacobson CA, Sun L, Kim HT, et al. Post transplant BAFF and B-cell recovery prior to onset of chronic GVHD. Biol Blood Marrow Transplant. 2014;20(5):668-675.
31. Hill GR, Olver SD, Kuns RD, et al. Stem cell mobilization with G-CSF induces type 17 differentiation and promotes scleroderma. Blood. 2010;116(5):819-828.
32. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29(16):2230-2239.
33. Min CK, Eom KS, Lee S, et al. Effect of induced GVHD in leukemia patients relapsing after allogeneic bone marrow transplantation: single-center experience of 33 adult patients. Bone Marrow Transplant. 2001;27(9):999-1005.